Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

Neurodegenerative Disorder
Alzheimer's Disease (AD)

For Medical Professional
Download

Basic Details

Sponsor Hoffmann-La Roche

Phase Phase 3

Trial Identifier NCT07177352, WP45722

Condition Alzheimers Disease

Official Title Master Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies as Assessed by Biomarker Status and Cognition

Study Summary

This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.

Eligibility Criteria

Gender

All

Age

≥50 Years & ≤ 90 Years

Healthy Volunteers

Inclusion Criteria

Report of objective or subjective memory concerns (by the participant and/or their informant) within the last year with or without a previous clinical diagnosis of MCI or dementia due to AD.

Exclusion Criteria

Dependency in basic activities of daily living (bADLs) due to cognitive impairment
Visual or auditory impairment that would prevent them from performing the cognitive assessments (eyeglasses and hearing aids are permitted)
Any self-reported evidence or known diagnosis of a neurological or neurodegenerative condition that may lead to cognitive impairment other than AD
History of severe, clinically significant central nervous system trauma
Any serious medical condition that precludes a participant's safe participation and completion of a clinical study

This page summarises information from public registry websites, such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. To learn more about this study, see the For Medical Professional tab or visit one of those websites.

The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

Results Disclaimer

What is Clinical Research?

In clinical research, volunteers, researchers, and medical professionals work together toward a shared goal: better treatment outcomes for patients. Clinical trials are vital to their process. They are carefully designed and follow approved protocols.

For the latest version of this information please go to www.forpatients.roche.com

Link to Third Party Site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Request a call back

First Name

Last Name

lblFpPhoneNumber

Products

When can we call you? (Free Service) 5am to 9am PST 9am to 1pm PST 1pm to 5pm PST

Don't want to wait for a callback ? Call us now

For Visitors from United States, our Privacy Statement can be reviewed below:
https://www.gene.com/privacy-policy

For Visitors from Canada, our Privacy Statement can be reviewed below:

http://www.rochecanada.com/en/content/footer-items/privacy.html

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

Basic Details

Study Summary

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

What is Clinical Research?

For the latest version of this information please go to www.forpatients.roche.com

YOU ARE ABOUT TO LEAVE THE GENENTECH CLINICAL TRIALS WEBSITE

Link to Third Party Site

Contact Genentech

Contact the hospital directly

Thank you

Request a call back

Find participating medical centers and current study status in each of them

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

For the latest version of this information please go to www.forpatients.roche.com